Institute of Radiation Physics, Lausanne University Hospital and Lausanne University, Lausanne, Switzerland.
Department of Radiation Oncology, Lausanne University Hospital and Lausanne University, Lausanne, Switzerland.
Radiother Oncol. 2024 Dec;201:110576. doi: 10.1016/j.radonc.2024.110576. Epub 2024 Oct 11.
This study explores the dosimetric feasibility and plan quality of hybrid ultra-high dose rate (UHDR) electron and conventional dose rate (CDR) photon (HUC) radiotherapy for treating deep-seated tumours with FLASH-RT.
HUC treatment planning was conducted optimizing a broad UHDR electron beam (between 20-250 MeV) combined with a CDR VMAT for a glioblastoma, a pancreatic cancer, and a prostate cancer case. HUC plans were based on clinical prescription and fractionation schemes and compared against clinically delivered plans. Considering a HUC boost treatment for the glioblastoma consisting of a 15-Gy-single-fraction UHDR electron boost supplemented with VMAT, two scenarios for FLASH sparing were assessed using FLASH-modifying-factor-weighted doses.
For all three patient cases, HUC treatment plans demonstrated comparable dosimetric quality to clinical plans, with similar PTV coverage (V within 0.5 %), homogeneity, and critical OAR-sparing. At the same time, HUC plans delivered a substantial portion of the dose to the PTV (D of 50-69 %) and surrounding tissues at UHDR. For the HUC boost treatment of the glioblastoma, the first FLASH sparing scenario showed a moderate FLASH sparing magnitude (10 % for D) for the 15-Gy UHDR electron boost, while the second scenario indicated a more substantial sparing of brain tissues inside and outside the PTV (32 % for D, 31 % for D).
From a planning perspective, HUC treatments represent a feasible approach for delivering dosimetrically conformal UHDR treatments, potentially mitigating technical challenges associated with delivering conformal FLASH-RT for deep-seated tumours. While further research is needed to optimize HUC fractionation and delivery schemes for specific patient cohorts, HUC treatments offer a promising avenue for the clinical transfer of FLASH-RT.
本研究探索了混合超高剂量率(UHDR)电子和常规剂量率(CDR)光子(HUC)放疗在FLASH-RT 治疗深部肿瘤中的剂量学可行性和计划质量。
针对胶质母细胞瘤、胰腺癌和前列腺癌病例,通过优化广谱 UHDR 电子束(20-250 MeV 之间)与 CDR VMAT 的组合,进行 HUC 治疗计划。HUC 计划基于临床处方和分割方案,并与临床交付的计划进行比较。考虑到 HUC 推量治疗,即由 15 Gy 单次剂量 UHDR 电子推量补充 VMAT 组成,使用 FLASH 修正因子加权剂量评估了两种 FLASH 节省方案。
对于所有三个患者病例,HUC 治疗计划在剂量学质量方面与临床计划相当,具有相似的 PTV 覆盖率(V 在 0.5%以内)、均匀性和关键 OAR 保护。同时,HUC 计划在 UHDR 下为 PTV 和周围组织提供了大量剂量(D 为 50-69%)。对于胶质母细胞瘤的 HUC 推量治疗,第一个 FLASH 节省方案显示 15 Gy UHDR 电子推量的适度 FLASH 节省幅度(D 为 10%),而第二个方案表明 PTV 内外脑组织的节省更为显著(D 为 32%,D 为 31%)。
从规划角度来看,HUC 治疗代表了一种可行的方法,可以提供剂量学一致的 UHDR 治疗,潜在缓解了为深部肿瘤提供一致的 FLASH-RT 所面临的技术挑战。虽然需要进一步研究来优化特定患者群体的 HUC 分割和交付方案,但 HUC 治疗为 FLASH-RT 的临床转化提供了有前途的途径。